1 | 1 | | HR0223LRB104 12931 MST 24484 r HR0223 LRB104 12931 MST 24484 r |
---|
2 | 2 | | HR0223 LRB104 12931 MST 24484 r |
---|
3 | 3 | | 1 HOUSE RESOLUTION |
---|
4 | 4 | | 2 WHEREAS, Myalgic encephalomyelitis (ME), also known as |
---|
5 | 5 | | 3 chronic fatigue syndrome (CFS), is a complex, debilitating |
---|
6 | 6 | | 4 neurological and immunological disease that affects millions |
---|
7 | 7 | | 5 worldwide, including an estimated two to three million people |
---|
8 | 8 | | 6 in the United States; and |
---|
9 | 9 | | 7 WHEREAS, ME/CFS is characterized by profound fatigue, |
---|
10 | 10 | | 8 post-exertional malaise, a worsening of symptoms after even |
---|
11 | 11 | | 9 minor exertion, cognitive impairment "brain fog", chronic |
---|
12 | 12 | | 10 pain, immune dysfunction, dizziness, and a range of other |
---|
13 | 13 | | 11 disabling symptoms that significantly reduce quality of life; |
---|
14 | 14 | | 12 and |
---|
15 | 15 | | 13 WHEREAS, ME/CFS can affect individuals of all ages, |
---|
16 | 16 | | 14 genders, and backgrounds, often leaving patients bedridden or |
---|
17 | 17 | | 15 housebound for years or even a lifetime, with only a small |
---|
18 | 18 | | 16 percentage achieving full recovery; and |
---|
19 | 19 | | 17 WHEREAS, Scientific research has demonstrated that ME/CFS |
---|
20 | 20 | | 18 is a serious, multi-system disease, yet it remains |
---|
21 | 21 | | 19 underfunded, under-researched, and widely misunderstood, |
---|
22 | 22 | | 20 contributing to significant delays in diagnosis, limited |
---|
23 | 23 | | 21 treatment options, and ongoing stigma for patients; and |
---|
24 | 24 | | |
---|
25 | 25 | | |
---|
26 | 26 | | |
---|
27 | 27 | | HR0223 LRB104 12931 MST 24484 r |
---|
28 | 28 | | |
---|
29 | 29 | | |
---|
30 | 30 | | HR0223- 2 -LRB104 12931 MST 24484 r HR0223 - 2 - LRB104 12931 MST 24484 r |
---|
31 | 31 | | HR0223 - 2 - LRB104 12931 MST 24484 r |
---|
32 | 32 | | 1 WHEREAS, Over 65 million people worldwide, including those |
---|
33 | 33 | | 2 suffering from long COVID and other post-viral conditions, now |
---|
34 | 34 | | 3 face similar challenges, highlighting the urgent need for |
---|
35 | 35 | | 4 increased biomedical research, healthcare provider education, |
---|
36 | 36 | | 5 and public awareness of infection-associated chronic |
---|
37 | 37 | | 6 conditions; and |
---|
38 | 38 | | 7 WHEREAS, The economic impact of ME/CFS in the U.S. alone |
---|
39 | 39 | | 8 is estimated to be in the hundreds of billions of dollars |
---|
40 | 40 | | 9 annually due to lost productivity, medical costs, and the need |
---|
41 | 41 | | 10 for full-time caregiving; and |
---|
42 | 42 | | 11 WHEREAS, Recognizing ME/CFS and related conditions as |
---|
43 | 43 | | 12 serious public health concerns will help accelerate research |
---|
44 | 44 | | 13 funding, improve clinical care, and promote policies that |
---|
45 | 45 | | 14 support affected individuals and their families; therefore, be |
---|
46 | 46 | | 15 it |
---|
47 | 47 | | 16 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE |
---|
48 | 48 | | 17 HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that |
---|
49 | 49 | | 18 we declare May 12, 2025 as Myalgic Encephalomyelitis/Chronic |
---|
50 | 50 | | 19 Fatigue Syndrome Awareness Day in the State of Illinois in |
---|
51 | 51 | | 20 recognition of the millions of people living with ME/CFS and |
---|
52 | 52 | | 21 related post-infectious diseases; and be it further |
---|
53 | 53 | | 22 RESOLVED, That suitable copies of this resolution be |
---|
54 | 54 | | |
---|
55 | 55 | | |
---|
56 | 56 | | |
---|
57 | 57 | | |
---|
58 | 58 | | |
---|
59 | 59 | | HR0223 - 2 - LRB104 12931 MST 24484 r |
---|
60 | 60 | | |
---|
61 | 61 | | |
---|
62 | 62 | | HR0223- 3 -LRB104 12931 MST 24484 r HR0223 - 3 - LRB104 12931 MST 24484 r |
---|
63 | 63 | | HR0223 - 3 - LRB104 12931 MST 24484 r |
---|
64 | 64 | | 1 presented to Gabriel Henry Hull and his mother, Rebbeca Groble |
---|
65 | 65 | | 2 Hull. |
---|
66 | 66 | | |
---|
67 | 67 | | |
---|
68 | 68 | | |
---|
69 | 69 | | |
---|
70 | 70 | | |
---|
71 | 71 | | HR0223 - 3 - LRB104 12931 MST 24484 r |
---|